The Cholesterol Particle Your Doctor Isn’t Testing — and Why It Matters
Your standard cholesterol panel – the one your doctor orders at your annual physical – does not measure lipoprotein(a). Most people have never heard of it. Yet roughly one in five people carries elevated levels of this inherited particle, and a major 2026 analysis of more than 20,000 adults found that very high amounts were linked to a 64% higher stroke risk and a 49% higher cardiovascular death risk, even when standard treatments were already in place.
The particle is called lipoprotein(a), abbreviated Lp(a) and often spoken aloud as “LP little a.” It is a cholesterol-carrying particle found in the blood that resembles LDL, or “bad” cholesterol, but includes an additional protein called apolipoprotein(a) that may make it more likely to contribute to cardiovascular disease. Lp(a) has been consistently identified as a significant risk factor for cardiovascular disease, with data linking elevated levels to an increased risk of ischemic stroke through pro-atherogenic, pro-inflammatory, and pro-thrombotic mechanisms.
Elevated Lp(a) levels are predominantly inherited and can raise cardiovascular risk even when traditional cholesterol levels are normal. Lp(a) levels are largely genetically determined, set at birth by inherited genes, and lifestyle changes such as diet, exercise, or weight loss have little to no impact on them. A person can eat well, exercise regularly, maintain a healthy weight, and still have high Lp(a) – because the body’s production of it is encoded in their DNA. Approximately one in five people has elevated Lp(a), and most are unaware because it usually does not cause symptoms.
What a study of 20,000 adults revealed about lipoprotein(a) stroke risk
Researchers analyzed blood samples from 20,070 adults aged 40 years and older who had participated in three large NIH trials: ACCORD, PEACE, and SPRINT. These trials were originally designed to investigate cardiovascular and metabolic health questions. The stored blood samples gave scientists an opportunity to ask a new question about Lp(a) years after the original data was collected, using a consistent laboratory method across all participants.
The average participant age was approximately 65, and roughly two-thirds were men. Researchers tracked major adverse cardiovascular events including myocardial infarction, stroke, coronary revascularization, and cardiac death. During a median follow-up of 3.98 years, 1,461 participants – 7.3% of the study population – experienced a major cardiovascular event.
The findings were presented at the SCAI 2026 Scientific Sessions in Montreal. People with Lp(a) levels of 175 nmol/L or higher had about a 31% higher risk of major cardiovascular events, a 49% higher risk of cardiovascular death, and a 64% higher risk of stroke. Those figures held up after researchers controlled for age, other illnesses, cholesterol levels, and existing treatments – meaning standard medical care was not eliminating the additional danger that high Lp(a) levels conferred.
Very high Lp(a) was not linked to a statistically significant increase in heart attack risk in this analysis. That distinction separates Lp(a) from LDL cholesterol, which raises the risk of heart attack and stroke roughly in parallel. The finding suggests Lp(a) may exert its most damaging effects through mechanisms especially relevant to stroke, such as promoting blood clots in the arteries supplying the brain, rather than simply accelerating the artery-narrowing process that leads to heart attacks.
The risk is sharper in people who already have heart disease
The increased risk was more pronounced in people who already had heart disease. Among that group, very high Lp(a) was associated with about a 30% higher risk of major cardiovascular events. Among people without established cardiovascular disease, the association was smaller and did not reach statistical significance – meaning researchers could not fully rule out chance.
For someone who already has coronary disease, an inherited Lp(a) burden adds another layer of danger on top of an already elevated baseline. Cardiologists managing patients with established heart disease may need to factor Lp(a) levels into their risk calculations and treatment decisions, not just LDL and blood pressure.
The SCAI findings also reinforce the value of your cholesterol numbers in full, rather than relying on a standard lipid panel alone.
Why diet and exercise won’t fix it
Most cardiovascular risk factors – LDL cholesterol, blood pressure, weight – respond to lifestyle changes. Lp(a) largely does not. Its levels are predominantly genetically determined, set at birth by genes inherited from one or both parents, and do not respond meaningfully to diet, exercise, or weight loss.
Statins, one of the most commonly prescribed classes of medication for heart disease, have minimal effect on Lp(a) levels. Lp(a) functions as an independent risk factor for coronary heart disease that standard lipid-lowering therapy cannot adequately address.
The practical response to high Lp(a) is to push harder on the risk factors that can be changed. Patients with high Lp(a) levels may benefit from more aggressive management of other cardiovascular risk factors – pushing LDL levels lower than standard targets, controlling blood pressure tightly, quitting smoking, and managing diabetes rigorously.
Why most people have never been tested
Despite elevated Lp(a) affecting roughly one in five adults, the vast majority have never had their levels measured. A standard cholesterol test does not include Lp(a). It requires a separate blood test, ordered specifically, and until recently few guidelines recommended doing so.
The 2026 ACC/AHA Dyslipidemia Guideline recommends universal once-in-a-lifetime Lp(a) measurement in all adults. The guideline describes Lp(a) as a well-recognized causal factor of atherosclerotic cardiovascular disease that acts independently of LDL cholesterol.
If you have a parent or sibling who experienced a heart attack or stroke at a young age, or if your cholesterol levels appear normal but you have other cardiac risk factors, an Lp(a) test is a reasonable conversation to raise with a physician.
New drugs that could change the picture
For years, no practical treatment specifically targeted Lp(a). Four medications currently in clinical trials – pelacarsen, olpasiran, lepodisiran, and muvalaplin – work primarily by interfering with the body’s production of apolipoprotein(a), the extra protein that gives Lp(a) its distinctive structure.
Olpasiran is currently in the phase 3 OCEAN(a) trial and has completed recruitment of over 7,200 patients with atherosclerotic cardiovascular disease and Lp(a) at 200 nmol/L or higher, with phase 2 results showing a 94% reduction in Lp(a). Lepodisiran, an investigational long-acting small interfering RNA therapy developed by Eli Lilly, lowered Lp(a) levels by more than 90 percentage points with a single 400 mg dose in the phase 2 ALPACA trial, according to Healio.
None of these drugs have received FDA approval yet. The critical question – whether lowering Lp(a) specifically reduces heart attacks and strokes – remains unanswered until large cardiovascular outcomes trials report their results. If those trials prove positive, lowering Lp(a) will become a new target in managing patients with elevated cardiovascular risk.
A single blood test is all it takes to find out your Lp(a) level. The 2026 ACC/AHA Dyslipidemia Guideline recommends that every adult have Lp(a) measured at least once in a lifetime. If your doctor hasn’t ordered one yet, ask for it specifically – it won’t appear on a standard cholesterol panel.
A high result doesn’t mean a heart attack or stroke is inevitable. People with high Lp(a) may benefit from more aggressive efforts to reduce other modifiable heart disease risk factors – working with a physician to set lower LDL targets, controlling blood pressure, eliminating smoking, and managing blood sugar if diabetes is present. If you have first-degree relatives with a history of early cardiovascular disease, encourage them to ask about Lp(a) testing too, since the condition is inherited and runs in families.
The SCAI 2026 findings are preliminary – presented at a conference and awaiting full peer-reviewed publication – and the study’s authors acknowledge that combining participants from different clinical trials introduces variability. With more than 20,000 participants, a standardized test method, and risk associations that persisted after accounting for age, other conditions, and treatment, the evidence is strong enough to prompt a conversation with your doctor about whether Lp(a) testing is appropriate for you.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
